FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2606784110> ?p ?o ?g. }

• W2606784110 abstract "Immuno-oncology (I-O) is a young and growing field on the frontier of cancer therapy. Contrary to cancer therapies that directly target malignant cells, I-O therapies stimulate the body’s immune system to target and attack the tumor, which is otherwise invisible to, or inhibiting the immune response. To this end, several methods have been developed: First, passive therapies that enable T-Cells to fight the tumor without direct manipulation, typically through binding and modifying the intracellular signaling of surface receptors. Checkpoint inhibitors, perhaps the most well-known of I-O therapies; are an example of such. These are monoclonal antibodies that block binding of the tumor cell at receptors that inactivate the T-Cell. A variety of small molecules can achieve the same effect by affecting metabolic or signaling pathways to boost the immune response or prevent its attenuation. Drugs originally formulated for unrelated disease states are now being used to treat cancer under the I-O approach. Second, active therapies which often involve direct manipulations that occur in vitro and once introduced to the patient will directly attack the tumor. Adoptive cell transfer is the oldest of these methods. It involves the removal of T-Cells from the body, which are then expanded and genetically modified for specificity towards tumor associated antigens (TAAs), and then reintroduced to the patient. A similar approach is taken with cancer vaccines, where TAAs are identified and reintroduced with adjuvants to stimulate an immune response, sometimes in the context of antigen presenting cells or viral vectors. Oncolytic viruses are genetically modified natural viruses for selectivity towards tumor cells. The resulting cytotoxicity has the potential to elicit an immune response that furthers tumor cell killing. A final active approach is bi-specific T-Cell engagers. These modified antibodies act to link a T-Cell and tumor cell through surface receptors and thereby forcibly generate immune recognition. The therapies in each of these sub-fields are all still very new and ongoing clinical trials could provide even further additions. The full therapeutic potential of the aforementioned therapies, alone or in combination, has yet to be realized, but holds great promise for the future of cancer treatment." @default.
• W2606784110 created "2017-04-28" @default.
• W2606784110 creator A5011375839 @default.
• W2606784110 creator A5054111631 @default.
• W2606784110 creator A5056838045 @default.
• W2606784110 creator A5059153674 @default.
• W2606784110 creator A5072905811 @default.
• W2606784110 date "2017-04-18" @default.
• W2606784110 modified "2023-10-14" @default.
• W2606784110 title "Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches" @default.
• W2606784110 cites W1532689189 @default.
• W2606784110 cites W1635229836 @default.
• W2606784110 cites W1740615695 @default.
• W2606784110 cites W1800636867 @default.
• W2606784110 cites W1891141189 @default.
• W2606784110 cites W1900415127 @default.
• W2606784110 cites W1962634412 @default.
• W2606784110 cites W1966999467 @default.
• W2606784110 cites W1970160028 @default.
• W2606784110 cites W1971882649 @default.
• W2606784110 cites W1975826537 @default.
• W2606784110 cites W1984815734 @default.
• W2606784110 cites W1987516241 @default.
• W2606784110 cites W1990602451 @default.
• W2606784110 cites W1997241837 @default.
• W2606784110 cites W2009487870 @default.
• W2606784110 cites W2010893633 @default.
• W2606784110 cites W2020329594 @default.
• W2606784110 cites W2020447109 @default.
• W2606784110 cites W2023685040 @default.
• W2606784110 cites W2029208213 @default.
• W2606784110 cites W2029910544 @default.
• W2606784110 cites W2043400006 @default.
• W2606784110 cites W2043980011 @default.
• W2606784110 cites W2046191057 @default.
• W2606784110 cites W2051962533 @default.
• W2606784110 cites W2054831292 @default.
• W2606784110 cites W2061662618 @default.
• W2606784110 cites W2063604248 @default.
• W2606784110 cites W2067067271 @default.
• W2606784110 cites W2069012164 @default.
• W2606784110 cites W2070748533 @default.
• W2606784110 cites W2085727125 @default.
• W2606784110 cites W2099489345 @default.
• W2606784110 cites W2101653483 @default.
• W2606784110 cites W2107556275 @default.
• W2606784110 cites W2108470072 @default.
• W2606784110 cites W2111877246 @default.
• W2606784110 cites W2117692326 @default.
• W2606784110 cites W2117800515 @default.
• W2606784110 cites W2118796952 @default.
• W2606784110 cites W2120963951 @default.
• W2606784110 cites W2132923173 @default.
• W2606784110 cites W2133105825 @default.
• W2606784110 cites W2141186092 @default.
• W2606784110 cites W2144256523 @default.
• W2606784110 cites W2146887062 @default.
• W2606784110 cites W2147947369 @default.
• W2606784110 cites W2148145202 @default.
• W2606784110 cites W2149486731 @default.
• W2606784110 cites W2153712501 @default.
• W2606784110 cites W2165038732 @default.
• W2606784110 cites W2169687232 @default.
• W2606784110 cites W2201278844 @default.
• W2606784110 cites W2209812019 @default.
• W2606784110 cites W2232866412 @default.
• W2606784110 cites W2255379229 @default.
• W2606784110 cites W2256675122 @default.
• W2606784110 cites W2263759961 @default.
• W2606784110 cites W2282215456 @default.
• W2606784110 cites W2285287574 @default.
• W2606784110 cites W2285363963 @default.
• W2606784110 cites W2296049142 @default.
• W2606784110 cites W2305814279 @default.
• W2606784110 cites W2313586256 @default.
• W2606784110 cites W2342267791 @default.
• W2606784110 cites W2345883861 @default.
• W2606784110 cites W2354242643 @default.
• W2606784110 cites W2413945457 @default.
• W2606784110 cites W2497822529 @default.
• W2606784110 cites W2570766240 @default.
• W2606784110 cites W2590326448 @default.
• W2606784110 cites W3117756250 @default.
• W2606784110 cites W4285719527 @default.
• W2606784110 cites W4292337452 @default.
• W2606784110 cites W82937767 @default.
• W2606784110 cites W4210985096 @default.
• W2606784110 doi "https://doi.org/10.3389/fonc.2017.00064" @default.
• W2606784110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5394116" @default.
• W2606784110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28459041" @default.
• W2606784110 hasPublicationYear "2017" @default.
• W2606784110 type Work @default.
• W2606784110 sameAs 2606784110 @default.
• W2606784110 citedByCount "41" @default.
• W2606784110 countsByYear W26067841102017 @default.
• W2606784110 countsByYear W26067841102018 @default.
• W2606784110 countsByYear W26067841102019 @default.
• W2606784110 countsByYear W26067841102020 @default.
• W2606784110 countsByYear W26067841102021 @default.
• W2606784110 countsByYear W26067841102022 @default.

• next